Detailed information for compound 349396

Basic information

Technical information
  • TDR Targets ID: 349396
  • Name: 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d ]pyrimidin-6-yl)-2-methoxyphenoxy]-N-phenylac etamide
  • MW: 434.445 | Formula: C23H22N4O5
  • H donors: 2 H acceptors: 3 LogP: 2.44 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1cc(ccc1OCC(=O)Nc1ccccc1)c1[nH]c2c(c1)n(C)c(=O)n(c2=O)C
  • InChi: 1S/C23H22N4O5/c1-26-17-12-16(25-21(17)22(29)27(2)23(26)30)14-9-10-18(19(11-14)31-3)32-13-20(28)24-15-7-5-4-6-8-15/h4-12,25H,13H2,1-3H3,(H,24,28)
  • InChiKey: HKTMAHFYXSEAQB-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-acetamide
  • 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-ethanamide
  • 2-[4-(2,4-diketo-1,3-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-acetamide
  • 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[4,5-d]pyrimidin-6-yl)-2-methoxyphenoxy]-N-phenylacetamide
  • 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[4,5-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-acetamide
  • 2-[4-(2,4-diketo-1,3-dimethyl-5H-pyrrolo[4,5-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-acetamide
  • 2-[4-(1,3-dimethyl-2,4-dioxo-5H-pyrrolo[4,5-d]pyrimidin-6-yl)-2-methoxy-phenoxy]-N-phenyl-ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens adenosine A2a receptor Starlite/ChEMBL References
Homo sapiens adenosine A2b receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi follicle stimulating hormone receptor adenosine A2a receptor 412 aa 336 aa 22.3 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Immunoglobulin I-set domain containing protein 0.0045 0.3486 0.1525
Echinococcus granulosus neurotracting:lsamp:neurotrimin:obcam 0.0042 0.3139 0.1123
Echinococcus multilocularis basic fibroblast growth factor receptor 1 A 0.0101 0.9674 1
Loa Loa (eye worm) hypothetical protein 0.0042 0.3139 0.1075
Schistosoma mansoni tyrosine kinase 0.0101 0.9674 1
Echinococcus multilocularis neuroglian 0.0038 0.2639 0.0443
Schistosoma mansoni Neurotrimin precursor (hNT) 0.0035 0.2313 0.2391
Schistosoma mansoni cell adhesion molecule 0.0042 0.3139 0.3245
Echinococcus multilocularis roundabout 2 0.0045 0.3465 0.1566
Echinococcus multilocularis fibroblast growth factor receptor 4 0.0101 0.9674 1
Loa Loa (eye worm) TK protein kinase 0.0104 1 1
Echinococcus granulosus fibroblast growth factor receptor 4 0.0101 0.9674 1
Echinococcus granulosus neuroglian 0.0038 0.2639 0.0443
Echinococcus granulosus twitchin 0.0038 0.2639 0.0443
Loa Loa (eye worm) TK/KIN16 protein kinase 0.0045 0.3486 0.1525
Loa Loa (eye worm) hypothetical protein 0.0045 0.3465 0.1499
Loa Loa (eye worm) hypothetical protein 0.0045 0.3465 0.1499
Echinococcus granulosus basic fibroblast growth factor receptor 1 A 0.0101 0.9674 1
Schistosoma mansoni nephrin 0.0038 0.2639 0.2728
Schistosoma mansoni vesicular amine transporter 0.0035 0.2313 0.2391
Echinococcus granulosus roundabout 2 0.0045 0.3465 0.1566
Schistosoma mansoni defective proboscis extension response (dpr)-related 0.0035 0.2313 0.2391

Activities

Activity type Activity value Assay description Source Reference
Inhibition (binding) = 10 % Displacement of [3H]DPCPX from recombinant human adenosine A2B receptor expressed in HeLa cells at 0.01 uM ChEMBL. 16392813
Inhibition (binding) = 10 % Displacement of [3H]DPCPX from recombinant human adenosine A2B receptor expressed in HeLa cells at 0.01 uM ChEMBL. 16392813
Inhibition (binding) = 20 % Displacement of [3H]ZM241385 from recombinant human adenosine A2A receptor expressed in HEK293 cells at 0.1 uM ChEMBL. 16392813
Inhibition (binding) = 20 % Displacement of [3H]ZM241385 from recombinant human adenosine A2A receptor expressed in HEK293 cells at 0.1 uM ChEMBL. 16392813
Inhibition (binding) = 27 % Displacement of [3H]DPCPX from recombinant human adenosine A2B receptor expressed in HEK293 cells at 0.1 uM ChEMBL. 16392813
Inhibition (binding) = 27 % Displacement of [3H]DPCPX from recombinant human adenosine A2B receptor expressed in HEK293 cells at 0.1 uM ChEMBL. 16392813
Ki (binding) = 6.52 Binding affinity to recombinant human adenosine A2A receptor ChEMBL. 16392813
Ki (binding) = 6.83 Binding affinity to recombinant human adenosine A2B receptor ChEMBL. 16392813
Log Ki (binding) = 6.52 Binding affinity to recombinant human adenosine A2A receptor ChEMBL. 16392813
Log Ki (binding) = 6.83 Binding affinity to recombinant human adenosine A2B receptor ChEMBL. 16392813
Ratio Ki (binding) = 2 Selectivity for human adenosine A2B over human adenosine A2A receptor ChEMBL. 16392813

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.